Blocking fatty acids' mystery tour: a therapy for metabolic syndrome?
Elevated circulating fatty acids are associated with impaired insulin action and inflammation. During intracellular transit, fatty acids use fatty acid-binding proteins (FABPs) as shuttles. A recent study (Furuhashi et al., 2007) explores inhibiting FABP4/aP2 as a strategy for treating atherosclerosis and type 2 diabetes.
Medical Department, Karl-Landsteiner Institute for Endocrinology and Metabolism, Heinrich-Collin-Strasse 30, A-1140 Vienna, Austria. michael.roden@meduniwien.ac.at
Michael
M
Roden
D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy*; D051379:Mice
D001713:Biphenyl Compounds; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids